Incretins and the development of type 2 diabetes
- 1 May 2006
- journal article
- review article
- Published by Springer Nature in Current Diabetes Reports
- Vol. 6 (3), 194-201
- https://doi.org/10.1007/s11892-006-0034-7
Abstract
The incretin hormones gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are released in response to nutrient ingestion and potentiate glucosestimulated insulin secretion from pancreatic β cells. The augmentation of postprandial insulin secretion by such gastrointestinal hormones is called the incretin effect. The incretin effect is almost completely absent in patients with type 2 diabetes. This is due to 1) an approximate 15% reduction in postprandial GLP-1 secretion and 2) a near total loss of insulinotropic activity of GIP. This review article summarizes clinical studies on abnormalities in the secretion and insulinotropic effects of GIP and GLP-1 in patients with type 2 diabetes as well as in individuals at high risk. A significant proportion of first-degree relatives are characterized by a reduced insulinotropic response to exogenous GIP. Nevertheless, this phenomenon does not predispose to a more rapid deterioration in glucose tolerance or conversion to impaired glucose tolerance or diabetes. Therefore, although there are hints of early abnormalities in incretin secretion and action in prediabetic populations, it has not been proven that such phenomena are central to the pathogenesis of type 2 diabetes.Keywords
This publication has 72 references indexed in Scilit:
- The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- To be or not to be--an incretin or enterogastrone?Gut, 2006
- A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cellsThe FASEB Journal, 2002
- Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patientsExperimental and Clinical Endocrinology & Diabetes, 1998
- Glucagonlike peptide 1Current Opinion in Endocrinology, Diabetes and Obesity, 1997
- Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)Nature, 1993
- What are ‘Physiological’ Plasma Gip Levels in Man After Intravenous Infusion of Porcine Gip?Scandinavian Journal of Gastroenterology, 1985
- Hamster preproglucagon contains the sequence of glucagon and two related peptidesNature, 1983
- The incretin concept todayDiabetologia, 1979
- Preparation of highly active enterogastroneCanadian Journal of Physiology and Pharmacology, 1969